AstraZeneca: Japan approves lung cancer drug
(CercleFinance.com) - AstraZeneca's cancer drug Tagrisso has been approved by Japanese authorities for an inoperable form of non-small cell lung cancer, the drugmaker said on Tuesday.
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Tagrisso for the first-line treatment of patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer, following priority review.
The approval is based on results from a Phase III trial in which Tagrisso showed superior progression-free survival of 18.9 months compared with 10.2 months for the comparator arm, the group said.
Tagrisso has now received approval in 40 countries.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Tagrisso for the first-line treatment of patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer, following priority review.
The approval is based on results from a Phase III trial in which Tagrisso showed superior progression-free survival of 18.9 months compared with 10.2 months for the comparator arm, the group said.
Tagrisso has now received approval in 40 countries.
Copyright (c) 2018 CercleFinance.com. All rights reserved.